Christopher Anzalone - Sep 27, 2022 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Chief Executive Officer, Director
Signature
/s/Christopher Anzalone
Stock symbol
ARWR
Transactions as of
Sep 27, 2022
Transactions value $
-$1,250,679
Form type
4
Date filed
9/29/2022, 05:15 PM
Previous filing
Jul 12, 2022
Next filing
Dec 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Options Exercise -$1.2M -39.1K -1.11% $30.77 3.47M Sep 27, 2022 Direct F1, F2
transaction ARWR Common Stock Options Exercise -$48.1K -1.54K -0.04% $31.21 3.47M Sep 27, 2022 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.21 to $31.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.21 to $31.25, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F4 Includes a total of 1,649,282 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.